Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Unicycive Therapeutics, Inc. (UNCY) ownership amendment reports that RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah each reported beneficial ownership of 3,091,590 common shares as of September 30, 2026, with shared voting and dispositive power over that amount and no sole power. These are overlapping reporting-person disclosures, not separate additional holdings: the Fund directly holds the securities, RA Capital is its investment adviser, and Kolchinsky and Shah are managers of RA Capital.
The Fund holds Tranche A, B and C Warrants relating to preferred stock convertible into 1,097,325, 997,568 and 1,596,109 common shares, respectively. A beneficial ownership blocker precludes conversion that would cause the Fund and attribution parties to own more than 9.99% of common stock; the amendment says the Fund is currently prohibited from converting to more than 3,091,590 shares. The narrative gives the ownership percentage as 9.99%; the cover pages round it down to 9.9%. The percentage calculation uses 27,855,257 common shares outstanding as of August 12, 2026.
Key Figures
Beneficial ownership reported by each reporting person:3,091,590 sharesBeneficial ownership percentage:9.99%Common shares outstanding:27,855,257 shares+3 more
6 metrics
Beneficial ownership reported by each reporting person3,091,590 sharesAs of September 30, 2026; each reported shared voting and dispositive power over this amount.
Beneficial ownership percentage9.99%Narrative percentage as of September 30, 2026; cover-page entries are rounded down to 9.9%.
Common shares outstanding27,855,257 sharesAs of August 12, 2026; denominator cited for the ownership percentage calculation.
Shares convertible from Series A-3 Preferred Stock1,097,325 sharesUnderlying Tranche A Warrants held directly by the Fund; subject to the beneficial ownership blocker.
Shares convertible from Series A-4 Preferred Stock997,568 sharesUnderlying Tranche B Warrants held directly by the Fund; subject to the beneficial ownership blocker.
Shares convertible from Series A-5 Preferred Stock1,596,109 sharesUnderlying Tranche C Warrants held directly by the Fund; subject to the beneficial ownership blocker.
Key Terms
Beneficial Ownership Blocker, Tranche A Warrants, Series A-3 Convertible Preferred Stock, shared voting power, +1 more
5 terms
Beneficial Ownership Blockerregulatory
"precludes the conversion of the Preferred Stock"
A beneficial ownership blocker is a legal or structural device that prevents a shareholder from being treated as the ultimate owner of enough shares to trigger control, reporting, or voting thresholds. Think of it like a speed bump that stops an investor from reaching a stake size that would force corporate disclosure or change control rights. Investors care because it affects who controls the company, how shares vote, regulatory filings, takeover risk and therefore potential value or liquidity of their holdings.
Tranche A Warrantsfinancial
"The Fund directly holds (i) Tranche A Warrants"
Series A-3 Convertible Preferred Stockfinancial
"shares of Series A-3 Convertible Preferred Stock"
shared voting powerregulatory
"Shared Voting Power 3,091,590.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerregulatory
"Shared Dispositive Power 3,091,590.00"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many UNCY shares did the reporting persons report owning?
Each of the four reporting persons reported beneficial ownership of 3,091,590 common shares as of September 30, 2026. The entries describe overlapping reporting-person positions: the Fund directly holds the securities, and the other reporting persons’ disclosures relate to that same reported position.
What is the UNCY beneficial ownership blocker?
The blocker precludes conversion of preferred stock to the extent the Fund, together with its affiliates and other attribution parties, would own more than 9.99% of UNCY common stock. The amendment states that the Fund is currently prohibited from converting to more than 3,091,590 common shares.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 8)
Unicycive Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
90466Y202
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
90466Y202
1
Names of Reporting Persons
RA Capital Management, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,091,590.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,091,590.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,091,590.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
90466Y202
1
Names of Reporting Persons
Peter Kolchinsky
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,091,590.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,091,590.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,091,590.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP Number(s):
90466Y202
1
Names of Reporting Persons
Rajeev Shah
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,091,590.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,091,590.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,091,590.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP Number(s):
90466Y202
1
Names of Reporting Persons
RA Capital Healthcare Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,091,590.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,091,590.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,091,590.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Unicycive Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
1975 W. El Camino Real, Suite 204, Mountain View, CA, 94040.
Item 2.
(a)
Name of person filing:
The names of the persons filing this report (collectively, the "Reporting Persons") are:
RA Capital Management, L.P. ("RA Capital")
Peter Kolchinsky ("Dr. Kolchinsky")
Rajeev Shah ("Mr. Shah")
RA Capital Healthcare Fund, L.P. (the "Fund")
The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G/A.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is:
c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116
(c)
Citizenship:
RA Capital and the Fund are Delaware limited partnerships.
Dr. Kolchinsky and Mr. Shah are United States citizens.
(d)
Title of class of securities:
Common Stock, $0.001 par value per share
(e)
CUSIP No.:
90466Y202
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
The Fund directly holds (i) Tranche A Warrants, through which it has the right to acquire shares of Series A-3 Convertible Preferred Stock ("A-3 Preferred Stock"), which are convertible into 1,097,325 shares of common stock, (ii) Tranche B Warrants, through which it has the right to acquire shares of Series A-4 Convertible Preferred Stock ("A-4 Preferred Stock"), which are convertible into 997,568 shares of common stock, and (iii) Tranche C Warrants, through which it has the right to acquire shares of Series A-5 Convertible Preferred Stock ("A-5 Preferred Stock"), which are convertible into 1,596,109 shares of common stock, all of which are subject to a Beneficial Ownership Blocker (as defined below).
The A-3, A-4, and A-5 Preferred Stock (collectively, the "Preferred Stock") are subject to a beneficial ownership blocker ("Beneficial Ownership Blocker"), which precludes the conversion of the Preferred Stock to the extent that, following conversion, the Fund, together with its affiliates and other attribution parties, would own more than 9.99% of the common stock outstanding. The Fund is currently prohibited from converting the Preferred Stock to the extent that such conversion would result in beneficial ownership of more than 3,091,590 shares of common stock.
RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund's portfolio, including the shares of the Issuer's Common Stock reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days' notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G/A other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G/A shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.
(b)
Percent of class:
Due to the Beneficial Ownership Blocker of the Preferred Stock, each Reporting Person's beneficial ownership percentage as of September 30, 2026 was 9.99%. The percentage set forth in each Row 11 is based upon 27,855,257 shares of the Issuer's common stock outstanding as of August 12, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 12, 2026, and giving effect to Preferred Stock, to the extent convertible within 60 days hereof, as referenced herein. Due to field limitations of the EDGAR filing system, the percentage listed in Row 11 of each Reporting Person's cover page has been rounded down to 9.9%.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
RA Capital Management, L.P.
Signature:
/s/ Peter Kolchinsky
Name/Title:
By Peter Kolchinsky, Authorized Signatory
Date:
11/16/2026
Peter Kolchinsky
Signature:
/s/ Peter Kolchinsky
Name/Title:
Peter Kolchinsky
Date:
11/16/2026
Rajeev Shah
Signature:
/s/ Rajeev Shah
Name/Title:
Rajeev Shah
Date:
11/16/2026
RA Capital Healthcare Fund, L.P.
Signature:
/s/ Peter Kolchinsky
Name/Title:
By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager
Date:
11/16/2026
Exhibit Information
Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G/A filed with the SEC on May 15, 2025).